Despite the setback with VY9323, Voyager Therapeutics anticipates IND filings in 2025 for gene therapy candidates targeting GBA1 Parkinson’s and other GBA1-mediated diseases, as well as Friedreich’s ...

New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

Voyager Therapeutics (VYGR) has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 amyotrophic ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs ...